July 10, 2024Open Access

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Inflammatory bowel disease (IBD), consists of two primary types: Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab (IFX) and Adalimumab (ADA) are frequently utilized in the management of moderate to severe cases of IBD.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kamal et al. (Wed,) studied this question.

synapsesocial.com/papers/68e60be9b6db64358759ea7f https://doi.org/https://doi.org/10.1007/s10787-024-01508-w

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy2023 · 10 citations
2Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs2015 · 59 citations
3A decade of inflammatory bowel disease: a single center experience in Egypt2022 · 7 citations
4Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring2021 · 23 citations
5Switching biologics used in inflammatory bowel diseases: how to deal with in practice?2020 · 7 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo